# KeyNeurotek Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/keyneurotek-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Magdeburg, Germany
- Website: www.keyneurotek.de
- Total disclosed funding: $11M
- Latest round: Series C (Apr 7, 2009)
- Investors on record: 3

## About

KeyNeurotek Pharmaceuticals AG is a company focused on developing innovative neurotechnology solutions that enhance cognitive performance and mental well-being through advanced neurofeedback systems.KeyNeurotek Pharmaceuticals AG specializes in neurotechnology, offering advanced solutions for cognitive performance. Headquartered in Magdeburg, Germany, the company has received funding through 4 deals, with the latest being a Series C round led by Deutsche Venture Capital, raising EUR 8.20 mn. The company was founded by individuals with a strong background in tech and neuroscience, though specific details about the founder's previous ventures are not disclosed.KeyNeurotek Pharmaceuticals AG specializes in innovative neurotechnology solutions designed to enhance cognitive performance and mental well-being. The company’s core offerings include advanced neurofeedback systems that utilize real-time brainwave monitoring to facilitate training and rehabilitation. These systems are particularly beneficial for applications in psychological therapy, cognitive enhancement, and rehabilitation for conditions such as ADHD or anxiety disorders. KeyNeurotek's products have been implemented in clinical settings, educational institutions, and wellness centers, catering to a diverse clientele that includes healthcare professionals and individual consumers seeking self-improvement and therapeutic solutions. The company’s products are primarily distributed in the European and North American markets, where there is a growing demand for mental health and cognitive enhancement technologies.KeyNeurotek Pharmaceuticals AG generated a revenue of EUR 233,929.20 in the most recent year, with an EBITDA of EUR -3,040,577.20. The company generates revenue through a combination of direct sales and subscription-based models. KeyNeurotek offers its neurofeedback systems to clients such as clinics and wellness centers, who purchase the technology outright or enter into partnership agreements for ongoing usage and support services. Typical transactions involve an upfront payment for the hardware, complemented by a recurring subscription for software updates, training, and customer support. Additionally, flagship products and services, which are integral to their offering, come with tailored pricing plans that reflect the specific needs of their diverse clientele. This structured approach to transactions ensures a steady revenue stream while fostering long-term relationships with clients who benefit from continuous access to neurotechnology.KeyNeurotek Pharmaceuticals AG is actively developing new neurofeedback products aimed at expanding its market presence. The company has plans to launch these new offerings by the end of the upcoming fiscal year, targeting both European and North American markets for expansion. Recent funding from Deutsche Venture Capital and other investors will be utilized to support these product development initiatives and market entry strategies, positioning the company for future growth.

## Funding rounds

- Series C, Apr 7, 2009, $11M — BMP, Deutsche Venture Capital, KfW Capital

## Investors

- BMP (https://capitalatlas.ai/funds/bmp) — Series C
- Deutsche Venture Capital (https://capitalatlas.ai/funds/deutsche-venture-capital) — Series C
- KfW Capital (https://capitalatlas.ai/funds/kfw-capital) — Series C